Cargando…

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma

Detalles Bibliográficos
Autores principales:	Postow, Michael, Manuel, Manuarii, Wong, Phillip, Yuan, Jianda, Noel, Marlene, Courtier, Anais, Pasqual, Nicolas, Wolchok, Jedd D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288372/ http://dx.doi.org/10.1186/2051-1426-2-S3-O8

Ejemplares similares

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
por: Postow, Michael A., et al.
Publicado: (2015)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
por: Page, David B, et al.
Publicado: (2014)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
por: Postow, Michael A, et al.
Publicado: (2014)

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients
por: Page, David B, et al.
Publicado: (2015)

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
por: Yuan, Jianda, et al.
Publicado: (2013)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
por: Callahan, Margaret K, et al.
Publicado: (2013)

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment()
por: Cassidy, Michael R., et al.
Publicado: (2017)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
por: Dummer, Reinhard, et al.
Publicado: (2015)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

ImmunTraCkeR(®) as a reliable TCR repertoire profiling tool to understand immune response and to explore immunotherapy biomarkers
por: Tanneau, Isabelle, et al.
Publicado: (2013)

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
por: Bartell, Heddy, et al.
Publicado: (2015)

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
por: Ku, Geoffrey Y, et al.
Publicado: (2010)

αβ-Double Negative CD4/CD8 (CD56) T cell (DNTs) in metastatic melanoma: basal frequency and behaviour during Ipilimumab treatment. Preliminary evaluations
por: De Tullio, Giacoma, et al.
Publicado: (2015)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
por: Rosner, Samuel, et al.
Publicado: (2018)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
por: Slingluff, Craig L., et al.
Publicado: (2021)

FcgRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via Ipilimumab-dependent ADCC in melanoma patients
por: Romano, Emanuela, et al.
Publicado: (2014)

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification
por: Hotson, Drew, et al.
Publicado: (2014)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection
por: Zamarin, Dmitriy, et al.
Publicado: (2013)

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters
por: Simeone, Ester, et al.
Publicado: (2014)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2015)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
por: Wolchok, Jedd D, et al.
Publicado: (2013)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients
por: Manuel, Manuarii, et al.
Publicado: (2012)

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2013)

Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
por: Pico de Coaña, Yago, et al.
Publicado: (2015)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi)
por: Page, David B, et al.
Publicado: (2014)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells
por: Sharma, Madhav, et al.
Publicado: (2015)

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production
por: Gentilcore, Giusy, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mf2pome3ps7hkv0f2ohnuf230b